JP2022115932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022115932A5 JP2022115932A5 JP2022074779A JP2022074779A JP2022115932A5 JP 2022115932 A5 JP2022115932 A5 JP 2022115932A5 JP 2022074779 A JP2022074779 A JP 2022074779A JP 2022074779 A JP2022074779 A JP 2022074779A JP 2022115932 A5 JP2022115932 A5 JP 2022115932A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- vector
- expression
- optionally
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 13
- 210000002865 immune cell Anatomy 0.000 claims 12
- 108091027967 Small hairpin RNA Proteins 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 9
- 239000000427 antigen Substances 0.000 claims 6
- 108091007433 antigens Proteins 0.000 claims 6
- 102000036639 antigens Human genes 0.000 claims 6
- 239000004055 small Interfering RNA Substances 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 102000014450 RNA Polymerase III Human genes 0.000 claims 1
- 108010078067 RNA Polymerase III Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023200890A JP7763824B2 (ja) | 2018-01-12 | 2023-11-28 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0004238 | 2018-01-12 | ||
| KR20180004238 | 2018-01-12 | ||
| PCT/IB2019/050194 WO2019138354A1 (en) | 2018-01-12 | 2019-01-10 | Enhanced immune cells using dual shrna and composition including the same |
| JP2020559043A JP7068498B2 (ja) | 2018-01-12 | 2019-01-10 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559043A Division JP7068498B2 (ja) | 2018-01-12 | 2019-01-10 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023200890A Division JP7763824B2 (ja) | 2018-01-12 | 2023-11-28 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022115932A JP2022115932A (ja) | 2022-08-09 |
| JP2022115932A5 true JP2022115932A5 (https=) | 2023-01-10 |
| JP7394914B2 JP7394914B2 (ja) | 2023-12-08 |
Family
ID=67218229
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559043A Active JP7068498B2 (ja) | 2018-01-12 | 2019-01-10 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
| JP2022074779A Active JP7394914B2 (ja) | 2018-01-12 | 2022-04-28 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
| JP2023200890A Active JP7763824B2 (ja) | 2018-01-12 | 2023-11-28 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020559043A Active JP7068498B2 (ja) | 2018-01-12 | 2019-01-10 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023200890A Active JP7763824B2 (ja) | 2018-01-12 | 2023-11-28 | 二重ｓｈＲＮＡを用いて強化された免疫細胞及びそれを含む組成物 |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11679129B2 (https=) |
| EP (2) | EP3737765B2 (https=) |
| JP (3) | JP7068498B2 (https=) |
| KR (2) | KR102805915B1 (https=) |
| CN (1) | CN111801421B (https=) |
| AU (2) | AU2019206425B2 (https=) |
| CA (1) | CA3088234A1 (https=) |
| DK (1) | DK3737765T4 (https=) |
| ES (2) | ES2908324T5 (https=) |
| FI (1) | FI3737765T4 (https=) |
| PL (1) | PL3737765T5 (https=) |
| PT (1) | PT3737765T (https=) |
| SG (1) | SG11202006606YA (https=) |
| WO (1) | WO2019138354A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20210069241A1 (en) * | 2017-10-20 | 2021-03-11 | Fred Hutchinson Cancer Research Center | Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression |
| EP3737765B2 (en) | 2018-01-12 | 2025-01-22 | Curocell Inc. | Enhanced immune cells using dual shrna and composition including the same |
| CN109485732B (zh) * | 2018-12-20 | 2021-09-24 | 四川大学华西医院 | 基因工程修饰的双靶点嵌合抗原受体及其用途 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY |
| EP3963076A1 (en) * | 2019-05-02 | 2022-03-09 | Celyad | Cells with multiplexed inhibitory rna |
| WO2021009701A1 (en) * | 2019-07-17 | 2021-01-21 | Curocell Inc. | Enhanced immune cells using dual shrna and composition including the same |
| AU2020322221A1 (en) | 2019-07-26 | 2022-03-24 | Janssen Biotech, Inc. | Anti-hK2 chimeric antigen receptor (CAR) |
| AU2020388690A1 (en) * | 2019-11-20 | 2022-06-09 | Cartherics Pty. Ltd. | Method for providing immune cells with enhanced function |
| GB202008688D0 (en) * | 2020-06-09 | 2020-07-22 | Cancer Research Tech Ltd | Chimeric antigen receptor cell |
| WO2022011065A1 (en) * | 2020-07-07 | 2022-01-13 | The Nemours Foundation | Tumor-activated alloreactive and xenoreactive t cells and their use in immunotherapy against cancer |
| CN114075562A (zh) * | 2021-03-10 | 2022-02-22 | 北京肿瘤医院(北京大学肿瘤医院) | Mage-c3抑制剂及其作为制备治疗和/或预防食管鳞状细胞癌药物的用途 |
| CN113416729B (zh) * | 2021-05-18 | 2022-11-22 | 遵义医科大学附属医院 | 一种肝脏靶向调控甲胎蛋白基因的shRNA和cDNA及其应用 |
| CN113403208A (zh) * | 2021-06-15 | 2021-09-17 | 江西科技师范大学 | 高效鉴定米曲霉CRISPR/Cas9突变体的方法 |
| EP4359533A2 (en) * | 2021-06-23 | 2024-05-01 | Versameb AG | Compositions and methods for modulating expression of genes |
| JP2024537991A (ja) | 2021-10-14 | 2024-10-18 | アーセナル バイオサイエンシズ インコーポレイテッド | 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞 |
| TW202342737A (zh) * | 2022-02-07 | 2023-11-01 | 中國大陸商杭州啟函生物科技有限公司 | 增強免疫療法的系統和方法 |
| EP4282963A1 (en) | 2022-05-23 | 2023-11-29 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | Nucleic acid modified biological cell with expansion-dependent gene expression |
| CN114836428B (zh) * | 2022-06-08 | 2024-03-26 | 华东师范大学 | 一种tigit基因干扰的嵌合抗原受体nk细胞及其应用 |
| WO2023238103A1 (en) * | 2022-06-10 | 2023-12-14 | Curocell Inc. | Car-t therapy for treating cancer |
| CN116983322B (zh) * | 2022-09-15 | 2026-04-07 | 圣诺生物医药技术(苏州)有限公司 | 用于治疗肺癌、胰腺癌、肝癌和结直肠癌的小核酸干扰药物 |
| IL322949A (en) | 2023-03-03 | 2025-10-01 | Arsenal Biosciences Inc | Systems targeting PSMA and CA9 |
| WO2024218204A1 (en) * | 2023-04-18 | 2024-10-24 | Uniqure Biopharma B.V. | Gene delivery vehicles comprising rna and antibodies |
| CN116515836B (zh) * | 2023-05-09 | 2023-12-01 | 中国人民解放军军事科学院军事医学研究院 | 抑制MerTK表达的shRNA、腺相关病毒及其应用 |
| CN117587014B (zh) * | 2023-11-24 | 2025-01-24 | 上海恩凯细胞技术有限公司 | 多功能基因修饰载体及其制备的多功能基因修饰免疫细胞和它们的应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| US20080293142A1 (en) * | 2007-04-19 | 2008-11-27 | The Board Of Regents For Oklahoma State University | Multiple shRNA Expression Vectors and Methods of Construction |
| EP2152874A2 (en) | 2007-04-26 | 2010-02-17 | University of Iowa Research Foundation | Rna interference suppression of neurodegenerative diseases and methods of use thereof |
| WO2012109667A1 (en) | 2011-02-12 | 2012-08-16 | University Of Iowa Research Foundation | Therapeutic compounds |
| MX2014001222A (es) * | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| CN103946952A (zh) | 2011-09-16 | 2014-07-23 | 宾夕法尼亚大学董事会 | 用于治疗癌症的rna改造的t细胞 |
| JP6647868B2 (ja) | 2013-02-20 | 2020-02-14 | ノバルティス アーゲー | ヒト化抗ＥＧＦＲｖＩＩＩキメラ抗原受容体を用いたがんの処置 |
| UY35468A (es) * | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2014191128A1 (en) | 2013-05-29 | 2014-12-04 | Cellectis | Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system |
| CA3051222C (en) | 2013-06-10 | 2023-01-24 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| ES2918501T3 (es) * | 2013-12-19 | 2022-07-18 | Novartis Ag | Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos |
| US20170335281A1 (en) | 2014-03-15 | 2017-11-23 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| AU2015244039B2 (en) * | 2014-04-07 | 2021-10-21 | Novartis Ag | Treatment of cancer using anti-CD19 chimeric antigen receptor |
| EP3146051B8 (en) | 2014-05-20 | 2019-11-27 | University of Iowa Research Foundation | Huntington's disease therapeutic compounds |
| US20170335331A1 (en) | 2014-10-31 | 2017-11-23 | The Trustees Of The University Of Pennsylvania | Altering Gene Expression in CART Cells and Uses Thereof |
| WO2016126608A1 (en) * | 2015-02-02 | 2016-08-11 | Novartis Ag | Car-expressing cells against multiple tumor antigens and uses thereof |
| ES2592578B1 (es) | 2015-05-07 | 2017-12-18 | Dode, S.A. | Mejoras introducidas en la patente de invención "Procedimiento para el tratamiento de granos de maíz destinados a la obtención de palomitas de maíz por medio de aparatos microondas y producto obtenido" |
| CA2997551A1 (en) * | 2015-09-04 | 2017-03-09 | Memorial Sloan Kettering Cancer Center | Immune cell compositions and methods of use |
| FI3380620T3 (fi) * | 2015-11-23 | 2024-08-01 | Novartis Ag | Optimoituja lentiviruksen siirtovektoreita ja niiden käyttötapoja |
| CN114823859A (zh) | 2015-12-11 | 2022-07-29 | 罗姆股份有限公司 | 半导体装置 |
| CN106967685B (zh) | 2016-01-13 | 2020-06-02 | 北京马力喏生物科技有限公司 | 共表达抗EGFRvIII嵌合抗原受体和免疫检查点抑制分子的转基因淋巴细胞及其用途 |
| CN106967681B (zh) | 2016-01-13 | 2020-06-05 | 北京马力喏生物科技有限公司 | 治疗脑胶质母细胞瘤的治疗组合物 |
| EP3219800A1 (en) | 2016-03-15 | 2017-09-20 | Max-Delbrück-Centrum Für Molekulare Medizin | A transposon-based transfection system for primary cells |
| US11111505B2 (en) * | 2016-03-19 | 2021-09-07 | Exuma Biotech, Corp. | Methods and compositions for transducing lymphocytes and regulating the activity thereof |
| WO2018012895A1 (ko) * | 2016-07-14 | 2018-01-18 | 주식회사 큐로셀 | 면역관문을 극복한 면역세포 및 상기 면역세포를 포함한 약제학적 조성물 |
| US20190309307A1 (en) | 2016-09-14 | 2019-10-10 | Benitec Biopharma Limited | REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOF |
| US12447213B2 (en) * | 2016-10-07 | 2025-10-21 | The Broad Institute, Inc. | Modulation of novel immune checkpoint targets |
| CN107058390A (zh) * | 2017-01-17 | 2017-08-18 | 上海交通大学医学院附属第九人民医院 | 一种慢病毒载体、重组慢病毒质粒、病毒及病毒的应用 |
| EP3585398A4 (en) * | 2017-02-23 | 2020-08-19 | Board of Regents of the University of Nebraska | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| EP3737765B2 (en) | 2018-01-12 | 2025-01-22 | Curocell Inc. | Enhanced immune cells using dual shrna and composition including the same |
| CN110904045A (zh) | 2018-09-17 | 2020-03-24 | 中国科学院动物研究所 | 经修饰的t细胞、其制备方法及用途 |
| WO2021009701A1 (en) | 2019-07-17 | 2021-01-21 | Curocell Inc. | Enhanced immune cells using dual shrna and composition including the same |
-
2019
- 2019-01-10 EP EP19738866.3A patent/EP3737765B2/en active Active
- 2019-01-10 CN CN201980016378.1A patent/CN111801421B/zh active Active
- 2019-01-10 CA CA3088234A patent/CA3088234A1/en active Pending
- 2019-01-10 PT PT197388663T patent/PT3737765T/pt unknown
- 2019-01-10 WO PCT/IB2019/050194 patent/WO2019138354A1/en not_active Ceased
- 2019-01-10 SG SG11202006606YA patent/SG11202006606YA/en unknown
- 2019-01-10 US US16/958,649 patent/US11679129B2/en active Active
- 2019-01-10 KR KR1020217036928A patent/KR102805915B1/ko active Active
- 2019-01-10 AU AU2019206425A patent/AU2019206425B2/en active Active
- 2019-01-10 DK DK19738866.3T patent/DK3737765T4/da active
- 2019-01-10 ES ES19738866T patent/ES2908324T5/es active Active
- 2019-01-10 JP JP2020559043A patent/JP7068498B2/ja active Active
- 2019-01-10 EP EP21207719.2A patent/EP4006153B1/en active Active
- 2019-01-10 ES ES21207719T patent/ES2990966T3/es active Active
- 2019-01-10 FI FIEP19738866.3T patent/FI3737765T4/fi active
- 2019-01-10 KR KR1020207023221A patent/KR102327512B1/ko active Active
- 2019-01-10 PL PL19738866.3T patent/PL3737765T5/pl unknown
-
2021
- 2021-03-18 US US17/205,951 patent/US20210260119A1/en not_active Abandoned
-
2022
- 2022-03-22 US US17/701,535 patent/US12285438B2/en active Active
- 2022-04-28 JP JP2022074779A patent/JP7394914B2/ja active Active
-
2023
- 2023-05-15 US US18/317,797 patent/US20230381236A1/en active Pending
- 2023-11-28 JP JP2023200890A patent/JP7763824B2/ja active Active
-
2025
- 2025-04-22 AU AU2025202789A patent/AU2025202789A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022115932A5 (https=) | ||
| Zhukovsky et al. | Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection | |
| JP2023542348A5 (https=) | ||
| US10604740B2 (en) | Nucleic acids encoding chimeric antigen receptor proteins which bind epidermal growth factor receptor and T lymphocyte expressing the protein | |
| JP2025111590A (ja) | 核酸を細胞に送達するための組成物および方法 | |
| JP2022512882A5 (https=) | ||
| FI3737765T4 (fi) | Parannettuja immuunisoluja käyttämällä kahta shRNA:ta ja niitä sisältäviä koostumuksia | |
| HRP20240494T1 (hr) | Kimerni antigenski receptori specifični za bcma i njihove upotrebe | |
| RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
| JP2020513829A5 (https=) | ||
| CN106967681B (zh) | 治疗脑胶质母细胞瘤的治疗组合物 | |
| RU2016129125A (ru) | Химерные рецепторы антигена против мезотелина человека и их применение | |
| CN114230670A (zh) | 靶向血液恶性肿瘤之嵌合抗原受体（car）、其组合物及使用方法 | |
| JP2017522879A5 (https=) | ||
| US11639496B2 (en) | Reducing fratricide of immune cells expressing NKG2D-based receptors | |
| JP2022509017A (ja) | 抗ｐｔｋ７免疫細胞癌療法 | |
| US20240190998A1 (en) | Compositions and methods for delivery of nucleic acids to cells | |
| US20230265214A1 (en) | Compositions and methods for delivery of nucleic acids to cells | |
| JP2023540041A5 (https=) | ||
| JP2022526720A5 (https=) | ||
| CN109554349B (zh) | Pd-1基因表达沉默的工程化免疫细胞 | |
| JP2021517454A5 (https=) | ||
| JP2023541456A5 (https=) | ||
| EP3974531A1 (en) | Asymmetric sirna inhibiting expression of pd-1 | |
| JP2022532998A (ja) | 選択的イントロンのスプライシングを調節するための方法及び組成物 |